drugset / Trial / NCT00405743
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with refractory or relapsed hematologic malignancies will receive CP-4055 intravenously(IV) on Day 1-5 every three weeks until complete response or disease worsening/progressing
Timeline
- Start
- 2006-05
- Primary completion
- 2009-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacytarabine | Small molecule | — | Intravenous |